Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 CD19 CAR T Cells.

Literature DB >> 29245005

CD19 CAR T Cells.

Abstract

CARs are synthetic receptors that reprogram immune cells for therapeutic purposes. They comprise three canonical domains for antigen recognition, T cell activation, and costimulation. The CAR cDNA is genetically integrated in the T cell genome. Autologous CAR T cells are generated from the patient's peripheral blood T cells and expand in the recipient to eliminate the targeted tumor. To view this Bench to Bedside, open or download the PDF.

Entities: Disease Gene Species

Mesh：

Substances：

Year: 2017 PMID： 29245005 DOI： 10.1016/j.cell.2017.12.002

Source DB: PubMed Journal: Cell ISSN： 0092-8674 Impact factor: 41.582

Keyword Cloud
Cited

34 in total

Review 1. Regulatory T cells in the treatment of disease.

Authors: Amir Sharabi; Maria G Tsokos; Ying Ding; Thomas R Malek; David Klatzmann; George C Tsokos
Journal: Nat Rev Drug Discov Date: 2018-10-12 Impact factor: 84.694

Review 2. Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy.

Authors: Elena García-Martínez; Melody Smith; Aitziber Buqué; Fernando Aranda; Francisco Ayala de la Peña; Alejandra Ivars; Manuel Sanchez Cánovas; Ma Angeles Vicente Conesa; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal: Oncoimmunology Date: 2018-02-15 Impact factor: 8.110

3. B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma.

Authors: Yu-Tzu Tai; Kenneth C Anderson
Journal: Expert Opin Biol Ther Date: 2019-07-11 Impact factor: 4.388

Review 4. Biomanufacturing for clinically advanced cell therapies.

Authors: Ayesha Aijaz; Matthew Li; David Smith; Danika Khong; Courtney LeBlon; Owen S Fenton; Ronke M Olabisi; Steven Libutti; Jay Tischfield; Marcela V Maus; Robert Deans; Rita N Barcia; Daniel G Anderson; Jerome Ritz; Robert Preti; Biju Parekkadan
Journal: Nat Biomed Eng Date: 2018-06-11 Impact factor: 25.671

Review 5. Genetically engineered CAR T-immune cells for cancer therapy: recent clinical developments, challenges, and future directions.

Authors: Sherien M El-Daly; Jihan Hussein
Journal: J Appl Biomed Date: 2019-02-20 Impact factor: 1.797

Review 10. Current and Future Role of Medical Imaging in Guiding the Management of Patients With Relapsed and Refractory Non-Hodgkin Lymphoma Treated With CAR T-Cell Therapy.

Authors: Laetitia Vercellino; Dorine de Jong; Roberta di Blasi; Salim Kanoun; Ran Reshef; Lawrence H Schwartz; Laurent Dercle
Journal: Front Oncol Date: 2021-05-28 Impact factor: 6.244

CD19 CAR T Cells.

Review 1. Regulatory T cells in the treatment of disease.

Review 2. Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy.

3. B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma.

Review 4. Biomanufacturing for clinically advanced cell therapies.

Review 5. Genetically engineered CAR T-immune cells for cancer therapy: recent clinical developments, challenges, and future directions.

6. Generation of Redirected Engineered Human Chimeric Antigen Receptor (CAR) T Cells.

Review 7. Precision medicine: In vivo CAR therapy as a showcase for receptor-targeted vector platforms.

8. Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial.

Review 9. Metabolic barriers to cancer immunotherapy.

Review 10. Current and Future Role of Medical Imaging in Guiding the Management of Patients With Relapsed and Refractory Non-Hodgkin Lymphoma Treated With CAR T-Cell Therapy.